The neuropeptide Y4 receptor (Y4) is a 375 amino acid G-protein coupled receptor (GPCR) that is ex- pressed mainly in peripheral tissues and the brain stem. In humans, Y4 belongs to a family of receptors (Y1, Y2, Y4, and Y5), that bind the ligands neuropeptide Y (NPY), polypeptide YY (PYY) and pancreatic polypeptide (PP). NPY, PYY and PP are 36 residue peptide hormones that play critical roles in regulating feeding behavior and energy homeostasis. Y4 is the only receptor subtype with low affinity for NPY and PYY and very high (picomolar) affinity for PP5. Thus, selective agonists of Y4 could be promising candidates for obesity therapeutics. In fact Obinepitide (TM-30338), a variant of PP and PYY, is currently in phase II clinical trials as a treatment for obesity. However as Obinepitide is a peptide, issues of stability and bioavailability remain. Development of non-peptidic Y4-selective ligands that bind to the endogenous binding site have failed so far. The objective of the present proposal is to identify small molecule allosteric modulators of the Y4 receptor. Allosteric modulators of GPCRs have a higher chance to be selective as allosteric binding sites tend to be evolutionary less conserved between receptor subtypes. The therapeutic potential of allosteric modulators is further increased by their ability to tune the receptor response instead of simply turning it on or off. Side effects may also be reduced for allosteric potentiators because the therapeutic only acts when the receptor is engaged by its native ligand. In preliminary work, we have adapted a Y4 functional assay for high-throughput screening (HTS) experiments that can detect agonists, antagonists and allosteric modulators simultaneously. We con- ducted a pilot screen of 2,000 compounds that yielded several hits including one, Niclosamide that displayed robust, selective allosteric potentiation with an EC50~400 nM. The proposed experiments will be used in combination with computational methods that enable virtual screening of millions of compounds. We will construct quantitative structure activity relationship (QSAR) models to create libraries focused around initial hit compounds and libraries enriched with novel chemotypes predicted to be Y4 allosteric modulators. Identification of small molecule allosteric modulators of Y4 will allow future development of pharmacological probes and can seed drug discovery programs in obesity.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Pawlyk, Aaron Christopher
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Schools of Medicine
United States
Zip Code
Li, Bian; Mendenhall, Jeffrey; Nguyen, Elizabeth Dong et al. (2017) Improving prediction of helix-helix packing in membrane proteins using predicted contact numbers as restraints. Proteins 85:1212-1221
Gajewski, Stefan; Waddell, Michael Brett; Vaithiyalingam, Sivaraja et al. (2016) Structure and mechanism of the phage T4 recombination mediator protein UvsY. Proc Natl Acad Sci U S A 113:3275-80
Sliwoski, Gregory; Schubert, Mario; Stichel, Jan et al. (2016) Discovery of Small-Molecule Modulators of the Human Y4 Receptor. PLoS One 11:e0157146
Fischer, Axel W; Bordignon, Enrica; Bleicken, Stephanie et al. (2016) Pushing the size limit of de novo structure ensemble prediction guided by sparse SDSL-EPR restraints to 200 residues: The monomeric and homodimeric forms of BAX. J Struct Biol 195:62-71
Sliwoski, Gregory; Mendenhall, Jeffrey; Meiler, Jens (2016) Autocorrelation descriptor improvements for QSAR: 2DA_Sign and 3DA_Sign. J Comput Aided Mol Des 30:209-17
Li, Bian; Mendenhall, Jeffrey; Nguyen, Elizabeth Dong et al. (2016) Accurate Prediction of Contact Numbers for Multi-Spanning Helical Membrane Proteins. J Chem Inf Model 56:423-34
Geanes, Alexander R; Cho, Hykeyung P; Nance, Kellie D et al. (2016) Ligand-based virtual screen for the discovery of novel M5 inhibitor chemotypes. Bioorg Med Chem Lett 26:4487-4491
Bornhop, Darryl J; Kammer, Michael N; Kussrow, Amanda et al. (2016) Origin and prediction of free-solution interaction studies performed label-free. Proc Natl Acad Sci U S A 113:E1595-604
Moretti, Rocco; Bender, Brian J; Allison, Brittany et al. (2016) Rosetta and the Design of Ligand Binding Sites. Methods Mol Biol 1414:47-62
Konduri, Kartik; Gallant, Jean-Nicolas; Chae, Young Kwang et al. (2016) EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. Cancer Discov 6:601-11

Showing the most recent 10 out of 31 publications